CELH
Celsius Holdings, Inc.
CELH has the edge over GHC overall, supported by stronger fundamentals and stronger modeled upside.
GHC
Graham Holdings Company
GHC has lower modeled downside risk, despite its lower overall score.
CELH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Strong |
CELH's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
GHC Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Under pressure | |
| Stable |
GHC's revenue, profitability and balance sheet are currently stable, but its cash flow is under pressure.
CELH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 21x | $31.89 | — |
| Current | 35x | $31.89 | — |
| Cheap | 40x | $35.95 | +13% |
| Fair | 141x | $127 | +299% |
| Expensive | 650x | $585 | +1735% |
Historical ranges are pointers, not guarantees.
CELH has the edge over GHC in the historical PE scenario, which offers more potential upside but is not a forecast.
GHC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 6.6x | $751 | -38% |
| Current | 11x | $1,213 | — |
| Fair | 12x | $1,363 | +12% |
| Expensive | 20x | $2,292 | +89% |
Historical ranges are pointers, not guarantees.
GHC's PE is in its fair range at 11x, but its recent earnings include one-off gains.
CELH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for CELH, with profitability improving. However, they disagree widely on these estimates.
GHC Forward outlook
There aren't enough analyst estimates for GHC to show an outlook.
CELH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.53 | +70% |
| Q3 2026 | $0.90 | +718% |
| Q2 2026 | $0.24 | -37% |
| Q1 2026 | $0.43 | +30% |
| Q4 2025 | $0.25 | -44% |
| Q3 2025 | $0.11 | -85% |
| Q2 2025 | $0.38 | -62% |
| Q1 2025 | $0.33 | -64% |
| Q4 2024 | $0.45 | -42% |
CELH earned $0.90 per share over the past year, about eight times what it earned the year before.
GHC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $113.84 | -31% |
| Q2 2026 | $124.15 | -20% |
| Q1 2026 | $67.64 | -52% |
| Q4 2025 | $66.47 | -59% |
| Q3 2025 | $165.76 | +225% |
| Q2 2025 | $154.27 | +421% |
| Q1 2025 | $141.13 | +134% |
| Q4 2024 | $163.40 | +276% |
GHC has the edge over CELH on earnings, with more consistent year-over-year improvement.
CELH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $847.2M | +17% |
| Q2 2026 | $817.9M | +11% |
| Q1 2026 | $782.6M | +138% |
| Q4 2025 | $721.6M | +117% |
| Q3 2025 | $725.1M | +173% |
| Q2 2025 | $739.3M | +84% |
| Q1 2025 | $329.3M | -7.4% |
| Q4 2024 | $332.2M | -4.4% |
CELH's revenue has grown year over year for six quarters in a row: $847M last quarter, up 17% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +31 points |
| Q2 2026 | 9.2% | -10 points |
| Q1 2026 | 18% | +2 points |
| Q4 2025 | 3.6% | +9.2 points |
| Q3 2025 | -11% | -9.8 points |
| Q2 2025 | 19% | -4.1 points |
| Q1 2025 | 16% | -7.6 points |
| Q4 2024 | -5.6% | -23 points |
CELH has the edge over GHC on profitability, with a higher operating margin.
GHC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.3B | +3.7% |
| Q2 2026 | $1.3B | +7.1% |
| Q1 2026 | $1.2B | +6% |
| Q4 2025 | $1.3B | +0.4% |
| Q3 2025 | $1.3B | +5.9% |
| Q2 2025 | $1.2B | +2.6% |
| Q1 2025 | $1.2B | +1.1% |
| Q4 2024 | $1.2B | +6.8% |
GHC's revenue has grown year over year for 22 quarters in a row: $1.3B last quarter, up 3.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.5% | +1.2 points |
| Q2 2026 | 6.4% | +0.4 points |
| Q1 2026 | 4.7% | +0.6 points |
| Q4 2025 | 3.8% | -2 points |
| Q3 2025 | 5.3% | -1.5 points |
| Q2 2025 | 6% | +3.8 points |
| Q1 2025 | 4.1% | +1 points |
| Q4 2024 | 5.8% | +2.3 points |
GHC's operating margin was 6.5% last quarter, up 1.2 points from the same quarter a year ago, near the top of its range since 2019.
CELH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $127.7M | -60% |
| Q2 2026 | $205.5M | +479% |
| Q1 2026 | $65.8M | -32% |
| Q4 2025 | -$130M | -285% |
| Q3 2025 | $321.5M | +3599% |
| Q2 2025 | $35.5M | +17% |
| Q1 2025 | $96.4M | -26% |
| Q4 2024 | $70.3M | +16394% |
CELH still generates free cash flow, though less than at its 2025 peak: $269M over the past year.
GHC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $134.6M | -17% |
| Q2 2026 | $32.6M | -58% |
| Q1 2026 | $48.6M | +59% |
| Q4 2025 | $5M | -94% |
| Q3 2025 | $161.8M | -26% |
| Q2 2025 | $78M | +131% |
| Q1 2025 | $30.5M | +$50.7M |
| Q4 2024 | $91.1M | +263% |
GHC still generates free cash flow, though less than at its 2024 peak: $221M over the past year.
CELH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.8% | -2M shares |
| 1 year | -1.1% | -2.9M shares |
| 3 years | +7.4% | +17.6M shares |
| 5 years | +8.3% | +19.5M shares |
| Available history | +32% | +62.4M shares |
CELH has 255M diluted shares, down 1.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $300,000 |
| Q2 2026 | $1M |
| Q1 2026 | $8.8M |
| Q4 2025 | $2.5M |
| Q3 2025 | $448,000 |
| Q2 2025 | $879,000 |
| Q1 2025 | $1.9M |
| Q4 2024 | $603,000 |
CELH spent $13M buying back its own shares over the past year, about three times what it spent the year before.
GHC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.5% | -66K shares |
| 1 year | -3.1% | -135K shares |
| 3 years | -7.8% | -359K shares |
| 5 years | -15% | -734K shares |
| Available history | -20% | -1.1M shares |
GHC has the edge over CELH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $76.6M |
| Q2 2026 | $87.8M |
| Q1 2026 | $34.1M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $3.5M |
| Q4 2024 | $15.9M |
GHC spent $199M buying back its own shares over the past year, more than ten times what it spent the year before.
CELH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.1x | Net Cash |
| Q2 2026 | 0.2x | Very low |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 1.6x | Healthy |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 1.4x | Healthy |
| Q1 2025 | -7.3x | Net Cash |
| Q4 2024 | -5.5x | Net Cash |
CELH has the edge over GHC on leverage, with a lower net debt burden relative to earnings.
GHC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.9x | Healthy |
| Q2 2026 | 2.1x | Moderate |
| Q1 2026 | 1.9x | Healthy |
| Q4 2025 | 1.8x | Healthy |
| Q3 2025 | 1.5x | Healthy |
| Q2 2025 | 1.7x | Healthy |
| Q1 2025 | 2.0x | Moderate |
| Q4 2024 | 1.4x | Healthy |
GHC's net debt is about 1.9 years of its operating earnings (EBITDA), up from 1.4 years a year ago.
CELH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.3 | Neutral |
| Stochastic | 56.8 | Neutral |
CELH's weekly RSI is 51 (neutral) and its Stochastic is 57 (neutral).
GHC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.1 | Neutral |
| Stochastic | 61.1 | Neutral |
GHC's weekly RSI is 59 (neutral) and its Stochastic is 61 (neutral).
CELH PE vs Consumer Defensive Sector
| Metric | CELH | Sector median | Relative |
|---|---|---|---|
| PE | 35x | 19x | 82% above |
| PE % | 11 | 18 | 7 pts below |
CELH is trading at 35x earnings, a 82% premium to the Consumer Defensive sector's median of 19x.
GHC PE vs Consumer Defensive Sector
| Metric | GHC | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 19x | 45% below |
| PE % | 45 | 18 | 27 pts above |
GHC has the edge over CELH on valuation relative to its sector.
CELH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.1 | 9.4% above |
| 20 week MA | $29.6 | 7.8% above |
| 50 week MA | $36.1 | 12% below |
| 100 week MA | $38.8 | 18% below |
| 200 week MA | $44.6 | 29% below |
CELH has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 29% below its 200-week average.
GHC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,186.0 | 2.3% above |
| 20 week MA | $1,174.4 | 3.3% above |
| 50 week MA | $1,136.3 | 6.8% above |
| 100 week MA | $1,057.6 | 15% above |
| 200 week MA | $870.8 | 39% above |
GHC has the edge over CELH on trend strength, trading above more of its moving averages.
CELH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.58 | $14.7 | +832% |
| 2021 | $14.7 | $24.9 | +69% |
| 2022 | $24.9 | $35.6 | +43% |
| 2023 | $35.6 | $54.5 | +53% |
| 2024 | $54.5 | $26.5 | -51% |
| 2025 | $26.5 | $45.6 | +72% |
| 2026 YTD | $45.6 | $31.9 | -30% |
CELH's yearly returns have swung widely, from +832% in 2020 to −51% in 2024. It's down 30% so far in 2026.
GHC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $639.4 | $524.1 | -18% |
| 2021 | $524.1 | $585.5 | +12% |
| 2022 | $585.5 | $597.4 | +2% |
| 2023 | $597.4 | $696.5 | +17% |
| 2024 | $696.5 | $879.0 | +26% |
| 2025 | $879.0 | $1,109.8 | +26% |
| 2026 YTD | $1,109.8 | $1,213.0 | +9.3% |
GHC has the edge over CELH on returns for 2026, with the stronger performance.